| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
|
Blood
|
2006
|
3.48
|
|
2
|
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
|
Lancet Oncol
|
2012
|
2.76
|
|
3
|
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.
|
Blood
|
2003
|
1.94
|
|
4
|
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
|
Cancer
|
2013
|
1.71
|
|
5
|
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
|
J Clin Oncol
|
2006
|
1.62
|
|
6
|
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.
|
Leuk Lymphoma
|
2011
|
1.21
|
|
7
|
Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions.
|
Cancer
|
2006
|
1.05
|
|
8
|
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.
|
J Clin Oncol
|
2009
|
0.97
|
|
9
|
Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
|
Cancer Chemother Pharmacol
|
2010
|
0.90
|
|
10
|
Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia.
|
J Clin Pharmacol
|
2004
|
0.88
|
|
11
|
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.
|
Am J Hematol
|
2015
|
0.86
|
|
12
|
An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).
|
J Neurooncol
|
2015
|
0.82
|
|
13
|
Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus.
|
Anticancer Res
|
2014
|
0.79
|
|
14
|
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
|
Br J Haematol
|
2014
|
0.79
|
|
15
|
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.76
|
|
16
|
Induction treatment for diffuse intrinsic pontine glioma, experience of M.D. Anderson Cancer Center.
|
Anticancer Res
|
2011
|
0.75
|
|
17
|
The association between opioid administration and response to therapy in patients with acute lymphoblastic leukemia.
|
Leuk Lymphoma
|
2015
|
0.75
|
|
18
|
Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ ALL resolution after decitabine therapy.
|
Pediatr Blood Cancer
|
2011
|
0.75
|
|
19
|
Langerhans cell histiocytosis with atypical histiocytic marrow infiltration.
|
Blood
|
2014
|
0.75
|